Breaking up Sedentary Time to Improve Glucose Control in a Population at

Status Recruiting

Clinical Trial Summary

Newly released guidelines recommend increased physical activity (PA) and reduced sedentary behaviors (SB) to improve glycemia and prevent the onset and progression of type 2 diabetes (T2D). Typically, 30-60 min bouts of PA are advocated per day. Although this approach increases PA, it does not decrease the length of the sedentary periods through the day. This is important because recent epidemiological data suggest that frequently interrupting sedentary time improves glucose control even in people who achieve the recommended levels of PA. Preliminary experimental data suggest that breaking up prolonged sedentary time by performing multiple short bouts (5 min) of PA throughout the day, may improve glycemia more than performing a single continuous bout of PA, and thereby potentially be a novel strategy to prevent T2D. The improvement in glycemia was observed even when the total amount of PA and total energy expenditure were matched, suggesting that how and when PA is performed over the day may matter more than how much PA is done. However, important gaps in knowledge remain including: (1) whether similar benefits on glucose control would be observed in adults with prediabetes, a clinically relevant population that is at high risk of developing T2D; (2) whether these effects are sustained or diluted over time, and (3) what are the mechanistic underpinnings. To address these gaps, the investigators propose to measure the acute and chronic effects of PA breaks on glucose control and the underlying mechanisms in individuals at risk of developing T2D. Sedentary men and women with prediabetes (n=66, 50% F) will be randomized to either an intervention designed to interrupt SB with 5-min bouts of brisk walking performed hourly for 9 hours/day, 5 days/week (BREAK) or a control condition consisting of 45-min of brisk walking performed as a single daily continuous bout, 5 days/week (ONE). The two 3-months interventions will be matched for total active time.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05041491
Study type	Interventional
Source	University of Colorado, Denver
Contact	Patricia Smith, MS, RDN
Phone	303.724.6821
Email	trish.smith@cuanschutz.edu
Status	Recruiting
Phase	Early Phase 1
Start date	November 30, 2021
Completion date	October 15, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04082585` - Total Health Improvement Program Research Project
Enrolling by invitation	`NCT05367024` - Broccoli Effect on Glycated Haemoglobin (HbA1c)	N/A
Withdrawn	`NCT02400450` - Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes	N/A
Completed	`NCT02933424` - Project Plant Protein: the P3 Study in Humans	N/A
Completed	`NCT02656212` - Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)	Phase 1
Completed	`NCT02330276` - Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin	Phase 1
Completed	`NCT01488279` - Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy	N/A
Completed	`NCT00831129` - A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs	Phase 2/Phase 3
Completed	`NCT00536250` - Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth	N/A
Recruiting	`NCT05563090` - Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools
Active, not recruiting	`NCT04991142` - Models of Nutrition From Continuous Glucose Monitors
Completed	`NCT02759055` - Pre-Diabetes Cardiovascular (CV) Care (Pre-Diabetes Wizard)	N/A
Completed	`NCT00775684` - Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass	N/A
Completed	`NCT03695913` - Continuous Glucose Monitoring (CGM) With a Low Carbohydrate Diet to Reduce Weight in Patients With Pre-Diabetes	N/A
Completed	`NCT04051008` - CTSI Pilot: Improving Adherence to Diabetic Diet	N/A
Recruiting	`NCT04897945` - A Shared Decision Making Intervention for Diabetes Prevention in Women With a History of Gestational Diabetes Mellitus	N/A
Not yet recruiting	`NCT04442451` - Mechanisms of Fatigability With Diabetes	N/A
Not yet recruiting	`NCT05925933` - High Protein Diet on Transcriptomic, Metabolomics, Hepatic and Pancreatic Fat Anatomy and Physiology in Asian Indians With Pre-diabetes	N/A
Active, not recruiting	`NCT05654051` - The SLIM LIVER Study	Phase 2
Completed	`NCT02919397` - Motivational Instant Messaging and E-diabetes Prevention Programme for High Risk of Type 2 Diabetes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes — BURST2D

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms